



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/00		A2	(11) International Publication Number: WO 99/52517 (43) International Publication Date: 21 October 1999 (21.10.99)
(21) International Application Number: PCT/IT99/00084 (22) International Filing Date: 8 April 1999 (08.04.99) (30) Priority Data: MI98A000774 10 April 1998 (10.04.98) IT (71) Applicant (for all designated States except US): SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. [IT/IT]; Viale Shakespeare, 47, I-00144 Rome (IT). (72) Inventors; and (75) Inventors/Applicants (for US only): CAVAZZA, Claudio [IT/IT]; Piazza Campitelli, 2, I-00186 Rome (IT). CAL- VANI, Menotti [IT/IT]; Via Longanesi, 14, I-00146 Rome (IT). (74) Agent: SPADARO, Marco; Sigma-Tau Industrie Farmaceu- tiche Riunite S.p.A., Viale Shakespeare, 47, I-00144 Rome (IT).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>Without international search report and to be republished upon receipt of that report.</i>	
(54) Title: COMPOSITION COMPRISING KETANSERIN AND L-CARNITINE OR AN ALKANOYL L-CARNITINE FOR THE TREATMENT OF CRPS			
(57) Abstract The use of ketanserine in combination with L-carnitine, some alkanoyl L-carnitines and the pharmacologically acceptable salts thereof is disclosed for the treatment of CRPS.			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LJ	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

**Composition comprising ketanserin and L-carnitine or an alkanoyl
L-carnitine for the treatment of CRPS**

Pharmaceutical composition for the treatment of Chronic
Regional Pain Syndrome

5 The present invention relates to L-carnitine and lower alkanoyl
L-carnitines or the pharmacologically acceptable salts thereof in
combination with ketanserin, for the therapeutic treatment of Chronic
Regional Pain Syndrome (CRPS).

10 CRPS is a pain syndrome, which affects several subjects after a
trauma, even a mild entity trauma.

To CRPS are associated disturbs of blood circulation with
ischemia and pain, wherein, ischemia gives pain and pain causes
ischemia.

15 Other important symptoms shown by patients affected by CRPS
are hyperpathia and allodinia.

CRPS origin is still not clear; for several years it has been
considered that the sympathetic nervous system is involved.

20 For this reason the most effective therapy was effected by
blocking the sympathetic innervation with phenol, thermolesion or
treating with guanethidine.

The circulation restoration with ketanserin, a serotonin
antagonist, constituted an improvement in the treatment of such
disease.

25 With this drug it is possible to treat most of symptoms, but not
those caused by hyperpathia and allodinia [A. Moesker et al., in


./.

Konservative Therapie Arterieller Durchblutungsstoerungen, Georg Thieme Verlag (Stuttgart, New York), 148-152, 1986; A. Moesker et al., The pain Clinic vol. 8, n°.1, 31-37 (1995); A. Moesker et al., ibid.vol 12, 269-302 (1991)].

5 More recently, following to the identification of the oxygen free radical during CRPS, dimethyl sulfoxide has been utilised (R. J. A. Goris et al. Free Rad. Res. Comm. 1987, 13-18; W. W. Zuurmond et al., Acta Anaesthesiol. Scan.) without any therapeutic result for the symptoms caused by hyperpathia and allodinia.

10 The therapeutic treatment with dimethyl sulfoxide proved to be efficacious only during acute CRPS.

Ketanserin is a well known synthetic drug (The Merck Index 11th Ed., pag. 834), having formula



and is a specific S₂-receptor antagonist with hypotensive properties, first described in EP application n°13.612.

Ketanserin has been utilised for evaluating its effect on central
20 haemodynamics and coronary circulation [J. Cardiovasc Pharmacol 1998 Dec; 32(6):983-7]; and
in the treatment of intermittent claudicatio [J. De Cree et al., Lancet 2, 775 (1984)].

./.

L-carnitine and alkanoyl L-carnitines are well known compounds. US Patent 4,255,449 and US Patent 4,268,524 describe the use of L-carnitine and alkanoyl L-carnitines, respectively, for normalising abnormally high ratios of low-density lipoproteins (LDL) +
5 very low- density lipoproteins (VLDL) to high-density lipoproteins (HDL), which constitute an etiological factor in various cardiovascular diseases. Through beta-oxidation of fatty acids, L-carnitine is capable of preventing their accumulation and of supplying the cell energy requirement (Bremner Y, *TIBS* 2, 207, 1977) via modulation of extra-
10 and intra-mitochondrial CoA.

L-carnitine and particularly propionyl L-carnitine or acetyl L-carnitine can act by varying the lipid substrate from which the various vasoconstrictor and aggregation-promoting factors derive as a result of the effects of cyclo-oxygenase and lipo-oxygenase, by reducing their
15 formation and by promoting the synthesis of antiaggregant and vasodilators factors.

Carnitine contain a single centre of asymmetry and therefore may exist as two enantiomers, designated D(+)-carnitine and L(-)-carnitine and, obviously in form of racemate. Of these only L(-)-
20 carnitine is found in living organism, were it functions as a vehicle for transporting fatty acids across mitochondrial membranes. Moreover, L-carnitine may be in form of inner salt or in form of pharmacologically acceptable salt.

./.

For the sake of simplicity in the following reference will be made only to L-carnitine or alkanoyl L-carnitine, it should be understood that the compositions described herein apply to L-carnitine or alkanoyl L-carnitines inner salt, or pharmacological acceptable salts thereof.

5 To date, the combined use of L-carnitine and ketanserin is not known for any therapeutic indication.

It has now unexpectedly been found that the co-ordinated use, a term which will be precisely defined here below, of L-carnitine or of an alkanoyl L-carnitine in which the linear or branched-chain alkanoyl
10 has 2-6 carbon atoms, or one of their pharmacologically acceptable salts, in combination with ketanserin show a potent synergistic effect in the treatment of CRPS.

With the composition of the invention patients are able either to recover from blood circulation symptoms or from hyperpathia and
15 allodinia symptoms.

This pharmacological activity is very important because for the first time it is possible to cure these symptoms in patients affected by CRPS.

The well known lack of toxic and side effects of L-carnitine or of
20 the alkanoyl L-carnitines and ketanserin makes their co-ordinated use, according to the invention, particularly useful and safe for the treatment of CRPS.

./.

In the context of the invention described herein, what is meant by "co-ordinated use" of the afore-mentioned compounds is either their co-administration, i.e. the substantially simultaneous administration of L-carnitine or one of the alkanoyl L-carnitines, or one of their pharmacologically acceptable salts, and ketanserin or, indifferently, the administration of a composition containing a combination or mixture of the aforesaid active ingredients, in addition to any excipient included.

The scope of the present invention therefore encompasses both the co-administration of L-carnitine or of an alkanoyl L-carnitine, or one of their pharmacologically acceptable salts, together with ketanserin and pharmaceutical compositions, which can be administered orally, parenterally or per intravenous infusion, containing a mixture of the two active ingredients.

In a preferred embodiment of the invention, the alkanoyl L-carnitine will be selected from the group consisting of acetyl, propionyl, butyryl, valeryl and isovaleryl L-carnitine or one of their pharmacologically acceptable salts.

What is meant by pharmacologically acceptable salt of L-carnitine or of an alkanoyl L-carnitine is any salt with an acid that does not give rise to unwanted toxic or side effects.

These acids are well known to pharmacologists and to experts in pharmacy.

./.

Examples of pharmacologically acceptable salts of L-carnitine or alkanoyl L-carnitine, though not exclusively these, are chloride, bromide, orotate, aspartate, acid aspartate, acid citrate, acid phosphate, fumarate and acid fumarate, lactate, maleate and acid maleate, mucate, acid oxalate, acid sulphate, glucose phosphate, tartrate and acid tartrate.

One preferred composition, in unit dosage form, is a composition containing 5-100 mg of ketanserin and 500-3000 mg of L-carnitine or an equivalent amount of alkanoyl L-carnitine.

10 This pharmaceutical composition is useful for the treatment of symptoms related to CRPS.

Here below are given, by way of example, the pharmacological results of experimental studies aimed at providing evidence of the surprising and unexpected synergistic effect achieved with the combination of the invention.

In the following description, reference will be made only to L-carnitine, it being understood that the compositions described also apply to the above-mentioned alkanoyl L-carnitines and to the pharmacologically acceptable salts of both L-carnitine and the above-mentioned alkanoyl L-carnitines.

Method of diagnosis of CRPS

The diagnosis of chronic regional pain syndrome was made in the presence of at least five of the following symptoms:

Persistent pain at rest;

5 Increasing pain during exercise;

Abnormal feeling of pain like hyperpathia or allodynia ;

Cold skin;

Glancing skin;

Hyperhidrosis;

10 Oedema;

Impaired mobility.

These symptoms were scored at the start of the treatment and after 3 months of oral treatment.

All patients gave their informed consent. Patients data are listed
15 in the following table 1.

TAB. 1

patient	M/F	Age (Years)	Delay (months)	Skin Tempera ture	Area
A	F	37	13	28.1	Foot
B	F	38	6	29.1	Foot
C	F	39	3	33.6	Hand
D	F	40	30	31.4	Hand
E	F	24	3	28.5	Foot
F	M	48	108	25.9	Foot
G	M	37	192	23.1	Foot
H	M	42	6	29.2	Knee
I	F	55	6	33.0	Hand
J	F	50	3	31.7	Hand
K	F	36	16	25.3	Hand
L	F	42	9	32.5	Foot
	Mean	40.7	32.9		
	S.D.	7.5	55.6		

All patient had a story of surgery on the affected area of hand,
5 foot, or knee.

In spite of the fact that this group comprised only 12 patients,
they matched with the general picture of CRPS patients found in
greater studies, like H. J. M. Veldman et al., The Lancet, 342, 1012-
1016 (1993).

./.

In a group of 829 CRPS patients Veldman had 76 % females and 24 % males. In the group treated according to the present invention, there were 67 % females and 33 % males.

The mean age of the Valdeman's study showed 42 years, in the study according to the example of the present invention, it was 40.7 years. Veldman found 59 % CRPS of the upper extremity and 41 % lower extremity.

In our group were 42 % CRPS of the upper extremity and 58 % CRPS of the lower extremity.

The delay time between start of the symptoms and start of the treatment was in our case of 33 months.

This extremely long time interval is the consequence of two patients with a delay of 108 and 192 months.

When we eliminate these two patients, delay time is reduced to 9.5 months, and for six patients delay time is six months or less.

Looking at the phenomenon of a warm or a cold CRPS the objective measurement of the skin temperature was used.

Taking into account that normal skin temperature is about 32 °C, 7 cold extremities and five normal or warm extremities were observed.

Special attention was given to the symptom of abnormal pain feeling, hyperpathia and allodinia.

This kind of symptom was found in 6 patients.

./.

Treatment

All i.v. treatments were performed after at least 15 minutes of acclimatisation at constant temperature (20-23 °C).

The temperature of the affected limb was recorded with Hewlett
5 Packard electro-skin probe between digit 4 and 5. In addition
continuous photoplethysmography of the affected hand (digit 2) or foot
(digit 1), blood pressure and heart rate were recorded.

All patients received a bolus of 10 mg of ketanserin i.v. in a
running saline infusion.

10 Ketanserin administration was continued by rate of 4 mg per
hour.

After one hour, a bolus injection of 1000 mg of L-carnitine was
given.

After this infusion start, oral maintenance therapy was started
15 with ketanserin three times daily 20 mg, and L-carnitine three times
daily 990 mg.

Results

To compare the clinical manifestation of the CRPS before and
after the infusion treatment followed by three months oral therapy an
20 evaluation of seven symptoms was made.

The seven symptoms were: pain at rest, pain during exercise,
impaired mobility, hyperhidrosis, oedema, small veins and
allodynia/hyperpathia.

./.

A scale with five degree was used. The nurse recorded the degree of the symptoms of the patient according to the following scale: absent, mild, reasonable, moderate and severe.

Fig. 1 shows the inventorisation at starting time; special
5 attention was given to the symptom allodynia, which is pointed on the first line.

This symptom was present in six out of these twelve patients. The results after three months are shown in Fig. 2.

After the intravenous treatment with ketanserin all patients had
10 peripheral circulation of the affected limb normalised, as proven in the past by Moesker (above cited) and by M. H. Hanna et al. [Pain, 38, 145-150 (1989)].

The symptom of small vein disappeared and the skin temperature was normalised.

15 After three months treatment with the two compounds according to the invention, patient "F" which was a severe case with a delay time of 108 months, had still the worst symptomatology, with pain at rest, pain during exercise and impaired mobility.

Patient "C" was a remarkably case, who had good recovery, but
20 still oedema and Hyperhidrosis.

Patient "B" was fully cured of any complaint of CRPS, despite she had a three months old full blow CRPS, with a skin temperature of 29,1 °C and seriously debilitating allodynia of the affected foot. Is

./.

noteworthy that the allodynia symptom disappeared in all patients that showed this symptom.

Impaired mobility and pain during exercise did not disappear completely probably because the treatment time with the combination
5 according to the present invention was too short.

Other positive results were obtained changing the therapeutic treatment protocol above cited.

In fact, it is possible to increase or decrease the amount of the two compounds either during the initial intravenous infusion or during
10 the maintenance therapeutic treatment (os).

In mild or recent CRPS it is possible to start directly with the above cited maintenance therapeutic treatment (os) with ketanserin and L-carnitine, three times daily.

It is an object of the present invention an orally or parenterally
15 administrable composition comprising ketanserin and L-carnitine or an alkanoyl L-carnitine or one of its pharmacologically acceptable salts.

Object of the present invention is also the co-ordinated use of the above-mentioned compounds i.e. the substantially simultaneous
20 administration of L-carnitine or one of the alkanoyl L-carnitines, or one of their pharmacologically acceptable salts, and ketanserin or, indifferently, the administration of a composition containing a

./.

combination or mixture of the aforesaid active ingredients, in addition to any excipient included.

The composition of the invention can be orally, parenterally or intravenously per infusion administered.

5 The composition according to the invention can be in the form of tablets, capsules, effervescent sachets, suppositories or vials.

Further object of the present invention is to provide a therapeutical kit comprising in the same package:

a) a first set of vials for intravenous infusion, said first set of vials
10 comprising 5-50 mg of ketanserin in admixture with pharmacologically acceptable vehicle and/or excipient, a second set of vials for intravenous infusion, said second set of vials comprising 500-2000 mg of L-carnitine or an equivalent amount of an alkanoyl L-carnitine or one pharmacologically acceptable salts
15 pharmaceutical composition comprising 100-3000 thereof, in admixture with pharmacologically acceptable vehicle and/or excipient;

and further comprising in the same package,

b) a first orally administrable pharmaceutical composition
20 comprising 5-100 mg of Ketanserin and a second orally administrable mg of L-carnitine or of an alkanoyl L-carnitine or one pharmacologically acceptable salts thereof, in admixture with pharmacologically acceptable vehicle and/or excipient.

./.

CLAIMS

1. A combination consisting of ketanserin and L-carnitine or an alkanoyl L-carnitine or one pharmacologically acceptable salts thereof.
- 5 2. Pharmaceutical composition comprising as active ingredients ketanserin and L-carnitine or an alkanoyl L-carnitine wherein the linear or branched-chain alkanoyl group has 2-6 carbon atoms or one pharmacologically acceptable salts thereof, in admixture with pharmacologically acceptable vehicle and/or excipient.
- 10 3. The composition according to claim 2, for oral, parenteral or intravenous infusion administration.
4. The composition according to claim 2, wherein the alkanoyl L-carnitine is selected from the group consisting of acetyl L-carnitine, propionyl L-carnitine, butyryl L-carnitine, valeryl L-carnitine and isovaleryl L-carnitine.
- 15 5. The composition according to claim 2, wherein the pharmacologically acceptable salt of L-carnitine or of the alkanoyl L-carnitine is selected from the group consisting of chloride, bromide, orotate, aspartate, acid aspartate, acid citrate, acid phosphate, fumarate and acid fumarate, lactate, maleate and acid maleate, mucate, acid oxalate, acid sulphate, glucose phosphate, tartrate and acid tartrate.
- 20

./.

6. The composition according to claim 2, in unit dosage form, comprising 5-100 mg of Ketanserin and 100-3000 mg of L-carnitine or of an alkanoyl L-carnitine.
7. The composition according to claim 6, suitable for oral administration.
8. The composition according to any of the preceding claims for the therapeutic treatment of CRPS.
9. Co-ordinated use of ketanserin and L-carnitine or of an alkanoyl L-carnitine or one of their pharmacologically acceptable salts for the treatment of CRPS.
10. A kit comprising in the same package a first set of vials for intravenous infusion, said first set of vials comprising 5-50 mg of ketanserin in admixture with pharmacologically acceptable vehicle and/or excipient, a second set of vials for intravenous infusion, said second set of vials comprising 500-2000 mg of L-carnitine or an equivalent amount of an alkanoyl L-carnitine wherein the linear or branched-chain alkanoyl group has 2-6 carbon atoms or one pharmacologically acceptable salts thereof, in admixture with pharmacologically acceptable vehicle and/or excipient.
11. A kit according to claim 10, further comprising in the same package a composition of claim 7.

./.

12. A kit according to claim 10 , further comprising in the same package a first orally administrable pharmaceutical composition comprising 5-100 mg of Ketanserin and a second orally administrable pharmaceutical composition comprising 100-3000 mg of L-carnitine or of an alkanoyl L-carnitine.
13. Use of ketanserin and L-carnitine or of an alkanoyl L-carnitine wherein the linear or branched-chain alkanoyl group has 2-6 carbon atoms or one of their pharmacologically acceptable salts for the preparation of a medicament for the treatment of CRPS.
14. Use according to claim 13, wherein the alkanoyl L-carnitine is selected from the group consisting of acetyl L-carnitine, propionyl L-carnitine, butyryl L-carnitine, valeryl L-carnitine and isovaleryl L-carnitine.
15. Use according to claim 13, wherein the pharmacologically acceptable salt of L-carnitine or of the alkanoyl L-carnitine is selected from the group consisting of chloride, bromide, orotate, aspartate, acid aspartate, acid citrate, acid phosphate, fumarate and acid fumarate, lactate, maleate and acid maleate, mucate, acid oxalate, acid sulphate, glucose phosphate, tartrate and acid tartrate.


./.

16. Use according to claim 13, wherein said medicament comprises, 5-100 mg of Ketanserin and 100-3000 mg of L-carnitine or of an alkanoyl L-carnitine, in a single unit dosage form.

17. Use according to claim 13, wherein said medicament comprises, 5-100 mg of Ketanserin in a first unit dosage form and 100-3000 mg of L-carnitine or of an alkanoyl L-carnitine in a second unit dosage form, said first and second unit dosage forms being physically separated between them.

./.

CRPS Symptomatology



CRPS Symptomatology after 3 month



THIS PAGE BLANK (USPTO)



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/505	A3	(11) International Publication Number: WO 99/52517 (43) International Publication Date: 21 October 1999 (21.10.99)
(21) International Application Number: PCT/IT99/00084 (22) International Filing Date: 8 April 1999 (08.04.99) (30) Priority Data: MI98A000774 10 April 1998 (10.04.98) IT (71) Applicant (for all designated States except US): SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. [IT/IT]; Viale Shakespeare, 47, I-00144 Rome (IT). (72) Inventors; and (75) Inventors/Applicants (for US only): CAVAZZA, Claudio [IT/IT]; Piazza Campitelli, 2, I-00186 Rome (IT). CAL- VANI, Menotti [IT/IT]; Via Longanesi, 14, I-00146 Rome (IT). (74) Agent: SPADARO, Marco; Sigma-Tau Industrie Farmaceu- tiche Riunite S.p.A., Viale Shakespeare, 47, I-00144 Rome (IT).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims</i> <i>and to be republished in the event of the receipt of amendments.</i> (88) Date of publication of the international search report: 6 January 2000 (06.01.00)
(54) Title: COMPOSITION COMPRISING KETANSERIN AND L-CARNITINE OR AN ALKANOYL L-CARNITINE FOR THE TREATMENT OF CRPS (57) Abstract The use of ketanserin in combination with L-carnitine, some alkanoyl L-carnitines and the pharmacologically acceptable salts thereof is disclosed for the treatment of CRPS.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K31/505

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No
P, X	MOESKER A.: "Treatment of hyperpathia/allodynia in CRPS, earlier called RSDS, a metabolic approach." PAIN CLINIC, (1998) 10/4 (261-274). , XP002119433 cited in the application the whole document ---	1-17
A	KINGERY W S: "A critical review of controlled clinical trials for peripheral neuropathic pain and complex regional pain syndromes." PAIN, (1997 NOV) 73 (2) 123-39. REF: 123 , XP002119434 page 128, left-hand column; table 4 --- -/--	1-3,8,9, 13

☒ Further documents are listed in the continuation of box C.

☐ Patent family members are listed in annex.

Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
 "E" earlier document but published on or after the international filing date
 "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
 "O" document referring to an oral disclosure, use, exhibition or other means
 "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
 "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
 "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
 "S" document member of the same patent family

Date of the actual completion of the international search

19 October 1999

Date of mailing of the international search report

17/11/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel (+31-70) 340-2040 Tx. 31 651 epo nl.
 Fax (+31-70) 340-3016

Authorized officer

Kanbier, D

INTERNATIONAL SEARCH REPORT

International Application No

PCT/IT 99/00084

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No
A	MOESKER: "The Purpose of a Serotonin Antagonist in Reflex Sympathetic Dystrophy" THE PAIN CLINIC, vol. 8, no. 1, 1995, pages 31-37, XP002119435 cited in the application page 33-34; figure 7 page 36 ---	1-3,8,9, 13
A	DANGEL T.: "Regional analgesia in children with reflex sympathetic dystrophy." MEDICAL SCIENCE MONITOR, (1997) 3/SUPPL. 1 (111-116). , XP002119436 page 114, right-hand column, paragraph 6 -----	1-3,8,9, 13

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 1-17 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims: it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

THIS PAGE BLANK (USPTO)